We are live on
!
Find out more
MLA
MB, Levis & Associates Portfolio holdings
AUM
$240M
1-Year Est. Return
12.17%
This Fund
S&P 500
This Quarter
Est. Return
-0.17%
1 Year Est. Return
+12.17%
3 Year Est. Return
+32.71%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$240M
AUM Growth
+$2.13M
(+0.9%)
Cap. Flow
+$4.23M
Cap. Flow
% of AUM
1.76%
Top 10 Holdings %
Top 10 Hldgs %
63.69%
Holding
256
New
11
Increased
72
Reduced
31
Closed
22
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
T. Rowe Price Dividend Growth ETF
TDVG
|
+$1.52M |
| 2 |
Capital Group Municipal Income ETF
CGMU
|
+$1.02M |
| 3 |
American Century US Quality Growth ETF
QGRO
|
+$221K |
| 4 |
iShares iBonds Dec 2032 Term Corporate ETF
IBDX
|
+$210K |
| 5 |
iShares iBonds Dec 2033 Term Corporate ETF
IBDY
|
+$207K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$137K |
| 2 |
Kinder Morgan
KMI
|
+$46.9K |
| 3 |
Merck
MRK
|
+$36.8K |
| 4 |
Automatic Data Processing
ADP
|
+$25.7K |
| 5 |
NextEra Energy
NEE
|
+$22.8K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 5.21% |
| 2 | Industrials | 4.87% |
| 3 | Healthcare | 3.48% |
| 4 | Financials | 2.88% |
| 5 | Consumer Staples | 2.07% |
Similar funds
CWM
SP
WFA
IIM
SIM
AFM
GBL
QFW
MB, Levis & Associates's Q1 2026 Portfolio in Review
As of Q1 2026, MB, Levis & Associates held 256 positions worth $240M, up 0.9% from $238M the previous quarter. Its ten largest holdings account for 64% of the portfolio.
MB, Levis & Associates's Q1 2026 filing shows 11 new, 72 increased, 31 reduced and 22 closed positions. Its largest new stake was Essential Utilities: 951 shares worth $38.3K. The largest sale was AstraZeneca, an estimated $137K.
By sector, the portfolio is most concentrated in Technology at 5.2% of assets, down from 6.2% a quarter earlier, followed by Industrials and Healthcare.
- MB, Levis & Associates's largest Q1 2026 buy was Essential Utilities: 951 shares worth $38.3K.
- MB, Levis & Associates added most to T. Rowe Price Dividend Growth ETF in Q1 2026, an estimated $1.52M increase.
- MB, Levis & Associates's biggest Q1 2026 reduction was Kinder Morgan, cutting an estimated $46.9K.
- MB, Levis & Associates fully exited AstraZeneca in Q1 2026, selling an estimated $137K.
- MB, Levis & Associates's ten largest holdings make up 64% of its $240M portfolio in Q1 2026.
- MB, Levis & Associates opened 11 new positions and closed 22 in Q1 2026.
- MB, Levis & Associates's portfolio value rose 0.9% quarter-over-quarter to $240M.
Based on MB, Levis & Associates's 13F filing for Q1 2026, filed 8 Apr 2026.